|Exchange:||NASDAQ national market|
|Zalicus, Inc., Delaware Corporation was incorporated in 2000. It is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The Company has a portfolio of proprietary clinical-stage product candidates targeting pain and has entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. All of its proprietary product candidates are focused in the area of pain, which is an area of continuing medical need with potentially large commercial markets. It is focused on discovering and developing new compounds that selectively target neuronal calcium and sodium channels for the treatment of pain. The Company has successfully completed Phase 1 clinical trials evaluating the pharmacokinetics and safety profiles of several new formulations of Z160, and the new formulations have demonstrated substantial bioavailability improvements. Its next advanced product candidate is Z944, a novel oral T-type calcium channel blocker that seeks to develop for the treatment of pain indications. Until September of 2012, the company had also been advancing the development of Synavive, a product candidate to treat immuno-inflammatory disorders. The Company has also been performing discovery research and preclinical development activities on its proprietary selective ion channel modulators targeting the Nav1.7 sodium channel as well as N-type and T-type calcium channels. It competes against a range of pharmaceutical, biotechnology and life science companies that have greater resources than the company.|
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.